NASDAQ:EYEG - Eyegate Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.56 -0.01 (-1.75 %)
(As of 06/24/2018 04:00 PM ET)
Previous Close$0.56
Today's Range$0.54 - $0.62
52-Week Range$0.29 - $1.47
Volume460,495 shs
Average Volume323,128 shs
Market Capitalization$23.78 million
P/E Ratio-0.55
Dividend YieldN/A
Beta3.53
Eyegate Pharmaceuticals logoEyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system. The company's CMHA-S based product, the EyeGate Ocular Bandage Gel, a topically-applied eye drop formulation that has completed its first-in-man clinical trial for the management of corneal epithelial wounds/defects and epitheliopathies, as well as to accelerate re-epithelization of the ocular surface following surgery, injection, and other traumatic and non-traumatic conditions. It is also developing EGP-437 for the treatment of various inflammatory conditions of the eye, including the treatment of ocular inflammation and pain in post-surgical cataract patients; and anterior uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and ciliary body, as well as Eyegate II drug delivery system. The company has license agreements with the University of Miami and its School of Medicine; subsidiaries of Valeant Pharmaceuticals International, Inc.; BioTime, Inc.; and the University of Utah Research Foundation. Eyegate Pharmaceuticals, Inc. is headquartered in Waltham, Massachusetts.

Receive EYEG News and Ratings via Email

Sign-up to receive the latest news and ratings for EYEG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EYEG
CUSIPN/A
Phone781-788-8869

Debt

Debt-to-Equity RatioN/A
Current Ratio1.18
Quick Ratio1.18

Price-To-Earnings

Trailing P/E Ratio-0.55
Forward P/E Ratio-1.14
P/E GrowthN/A

Sales & Book Value

Annual Sales$410,000.00
Price / Sales57.01
Cash FlowN/A
Price / CashN/A
Book Value($0.11) per share
Price / Book-5.09

Profitability

EPS (Most Recent Fiscal Year)($1.02)
Net Income$-13,210,000.00
Net Margins-2,480.28%
Return on Equity-653.57%
Return on Assets-93.74%

Miscellaneous

Employees17
Outstanding Shares41,740,000

The Truth About Cryptocurrencies

Eyegate Pharmaceuticals (NASDAQ:EYEG) Frequently Asked Questions

What is Eyegate Pharmaceuticals' stock symbol?

Eyegate Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYEG."

How were Eyegate Pharmaceuticals' earnings last quarter?

Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) released its quarterly earnings results on Friday, May, 11th. The specialty pharmaceutical company reported ($0.14) EPS for the quarter, beating analysts' consensus estimates of ($0.24) by $0.10. The specialty pharmaceutical company earned $1.10 million during the quarter, compared to analysts' expectations of $0.49 million. Eyegate Pharmaceuticals had a negative return on equity of 653.57% and a negative net margin of 2,480.28%. View Eyegate Pharmaceuticals' Earnings History.

What price target have analysts set for EYEG?

1 brokerages have issued 1-year price objectives for Eyegate Pharmaceuticals' stock. Their predictions range from $3.00 to $3.00. On average, they anticipate Eyegate Pharmaceuticals' share price to reach $3.00 in the next twelve months. View Analyst Ratings for Eyegate Pharmaceuticals.

Are investors shorting Eyegate Pharmaceuticals?

Eyegate Pharmaceuticals saw a decline in short interest in May. As of May 31st, there was short interest totalling 537,432 shares, a decline of 27.5% from the May 15th total of 741,705 shares. Based on an average daily trading volume, of 610,854 shares, the short-interest ratio is presently 0.9 days. Currently, 1.5% of the shares of the stock are short sold. View Eyegate Pharmaceuticals' Current Options Chain.

Who are some of Eyegate Pharmaceuticals' key competitors?

Who are Eyegate Pharmaceuticals' key executives?

Eyegate Pharmaceuticals' management team includes the folowing people:
  • Mr. Stephen From, Pres, CEO & Director (Age 55)
  • Dr. Barbara M. Wirostko, Chief Medical Officer (Age 52)
  • Mr. Michael P. Manzo, VP of Engineering (Age 59)
  • Ms. Sarah Romano, Chief Financial Officer
  • Mr. Paul Perkins, Sr. Director of Fin. & HR and Director of Fin.

When did Eyegate Pharmaceuticals IPO?

(EYEG) raised $5 million in an initial public offering on Friday, February 13th 2015. The company issued 800,000 shares at a price of $6.00 per share. Aegis Capital Corp and Chardan Capital Markets acted as the underwriters for the IPO.

Has Eyegate Pharmaceuticals been receiving favorable news coverage?

Press coverage about EYEG stock has trended somewhat negative this week, Accern Sentiment Analysis reports. The research group ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Eyegate Pharmaceuticals earned a media sentiment score of -0.18 on Accern's scale. They also assigned news coverage about the specialty pharmaceutical company an impact score of 46.38 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Who are Eyegate Pharmaceuticals' major shareholders?

Eyegate Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include ARMISTICE CAPITAL, LLC (40.20%), ARMISTICE CAPITAL, LLC (50.80%) and ARMISTICE CAPITAL, LLC (4.99%). Company insiders that own Eyegate Pharmaceuticals stock include Armistice Capital Master Fund, Morton Goldberg, Sarah Romano and Stephen From. View Institutional Ownership Trends for Eyegate Pharmaceuticals.

How do I buy shares of Eyegate Pharmaceuticals?

Shares of EYEG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eyegate Pharmaceuticals' stock price today?

One share of EYEG stock can currently be purchased for approximately $0.56.

How big of a company is Eyegate Pharmaceuticals?

Eyegate Pharmaceuticals has a market capitalization of $23.78 million and generates $410,000.00 in revenue each year. The specialty pharmaceutical company earns $-13,210,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Eyegate Pharmaceuticals employs 17 workers across the globe.

How can I contact Eyegate Pharmaceuticals?

Eyegate Pharmaceuticals' mailing address is 271 WAVERLEY OAKS ROAD SUITE 108, WALTHAM MA, 02452. The specialty pharmaceutical company can be reached via phone at 781-788-8869.


MarketBeat Community Rating for Eyegate Pharmaceuticals (EYEG)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  180 (Vote Outperform)
Underperform Votes:  88 (Vote Underperform)
Total Votes:  268
MarketBeat's community ratings are surveys of what our community members think about Eyegate Pharmaceuticals and other stocks. Vote "Outperform" if you believe EYEG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EYEG will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.